Compare Abbott Laboratories (ABT) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Abbott Laboratories trades at $95.6 (market cap $166.94B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $59.82 (market cap $77.30B). The key difference: Abbott Laboratories is far larger — about 2.2× MONDELEZ INTERNATIONAL INC Common Stock's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.32%). Which is the better fit depends on your goals.
| ABT | MDLZ | |
|---|---|---|
Market Cap | $166.94B | $77.30B |
Sector | Health | Consumer Staples |
52-Week High | $136.62 | $70.75 |
52-Week Low | $82.57 | $51.51 |
Enterprise Value | $193.69B | $97.40B |
Dividend Yield | 2.63% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
MDLZ trades at $60.22, down 1.13% today, with a bearish technical signal but strong fundamentals including consistent earnings beats and a 75.6% analyst buy rating. Revenue grew to $38.54B in 2025, though net margin compressed to 6.36%. Recent news highlights innovation in brands like Toblerone and Sour Patch Kids, alongside a new CFO appointment and a $0.50 dividend declaration.
Outlook: Wall Street consensus target of $67.86 suggests 12.7% upside, supported by resilient snacking demand and cost management. Risks include cocoa price volatility and competitive pressures, but the stock offers value with a P/E of 29.3 and stable cash flows, positioning it for recovery if technical resistance at $61 is breached.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
